{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:08:43Z","timestamp":1770977323642,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jac\/dky363","type":"journal-article","created":{"date-parts":[[2018,8,19]],"date-time":"2018-08-19T07:13:28Z","timestamp":1534662808000},"source":"Crossref","is-referenced-by-count":21,"title":["Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL- and AmpC-producing Enterobacteriaceae"],"prefix":"10.1093","author":[{"given":"David M","family":"Livermore","sequence":"first","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK"},{"name":"Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazad","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Doumith","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Jamrozy","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wright W","family":"Nichols","sequence":"additional","affiliation":[{"name":"Development Microbiology, AstraZeneca, Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Woodford","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"key\n\t\t\t\t20180920121151_dky363-B1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","article-title":"A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens","volume":"46","author":"Bush","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180920121151_dky363-B2","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180920121151_dky363-B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/31.suppl_A.9","article-title":"Determinants of the activity of \u03b2-lactamase inhibitor combinations","volume":"31","author":"Livermore","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015\u201316","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1469-0691.2007.01849.x","article-title":"IRT and CMT \u03b2-lactamases and inhibitor resistance","volume":"14","author":"Cant\u00f3n","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180920121151_dky363-B6","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1128\/AAC.42.12.3328","article-title":"Caz-hi, an extended-spectrum TEM \u03b2-lactamase (TEM-61), is derived from Caz-lo (TEM-11) by in vivo selection","volume":"42","author":"Claeys","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B7","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/jac\/dkt278","article-title":"In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy","volume":"68","author":"Jacquier","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B8","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jac\/dks079","article-title":"Characterization of \u03b2-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline\u200a+\u200aavibactam (NXL104)","volume":"67","author":"Livermore","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B9","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180920121151_dky363-B11","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B12","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/jac\/dkx179","article-title":"Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate","volume":"72","author":"Both","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jac\/38.3.409","article-title":"Antibiotic resistance and production of extended-spectrum \u03b2-lactamases amongst Klebsiella spp. from intensive care units in Europe","volume":"38","author":"Livermore","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jac\/dkl217","article-title":"Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England","volume":"58","author":"Potz","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B15","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1469-0691.1999.tb00721.x","article-title":"In vitro selective concentrations of cefepime and ceftazidime for AmpC \u03b2-lactamase hyperproducer Enterobacter cloacae variants","volume":"5","author":"Negri","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180920121151_dky363-B16","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"key\n\t\t\t\t20180920121151_dky363-B17","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/jac\/dkw230","article-title":"New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595\/RG6080","volume":"71","author":"Doumith","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B18","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"key\n\t\t\t\t20180920121151_dky363-B19","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/jac\/dku237","article-title":"Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C \u03b2-lactamase enzyme","volume":"69","author":"Lahiri","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2958.1990.tb00681.x","article-title":"Signal transduction and gene regulation through the phosphorylation of two regulatory components: the molecular basis for the osmotic regulation of the porin genes","volume":"4","author":"Mizuno","year":"1990","journal-title":"Mol Microbiol"},{"key":"key\n\t\t\t\t20180920121151_dky363-B21","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B22","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF02013107","article-title":"Clinical significance of \u03b2-lactamase induction and stable derepression in Gram-negative rods","volume":"6","author":"Livermore","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"key\n\t\t\t\t20180920121151_dky363-B24","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/28.5.669","article-title":"Selection and characterization of cefepime-resistant Gram-negative bacteria","volume":"28","author":"Piddock","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/AAC.01173-15","article-title":"\u03b2-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates","volume":"60","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B27","doi-asserted-by":"crossref","first-page":"e02447","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular \u03b2-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections: efficacies analyzed against susceptible and resistant subsets","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180920121151_dky363-B28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dky363\/25814474\/dky363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T11:13:55Z","timestamp":1571742835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dky363\/5104447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1093\/jac\/dky363","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]}}}